MarketLens
Sign Up

Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest

6 months ago
SHARE THIS ON:

Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 week ago

Ondas, SoundHound AI Among 5 Stocks Facing Heavy Short Bets

Ondas (ONDS) leads five stocks with heavy short bets, as short interest hit 40.40% of shares outstanding, reflecting bearish sentiment amid ongoing losses.
Stock News1 months ago

NextCure, Inc. (NASDAQ:NXTC) Sees Large Increase in Short Interest

NextCure (NXTC) short interest surged 734.7% to 1.32M shares as of July 15, versus 158,592 on June 30. About 41.6% of shares are now short.
Stock News2 months ago

NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?

Intellia (NTLA) surged 38% in a month after positive Phase III lonvo-z data and pipeline progress boosted investor optimism.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

$10,000 in Tesla When It Joined the S&P 500 Would Be About $15,700 Today. An Index Fund Would Have Done Better.

Stock News4 hours ago

J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion

Stock News5 hours ago

Google's Historic 396 MW Clean Energy Deal Just Changed the Game for 1 AI Power Play

Stock News6 hours ago

Better AI Chip Stock: Broadcom vs. Nvidia

Stock News6 hours ago

Dell Technologies Sees AI Boom Building as $95B Server Backlog Signals Demand